Skip to main content

Table 3 Secondary safety outcomes

From: Efficacy and safety of oxygen-sparing nasal reservoir cannula for treatment of pediatric hypoxemic pneumonia in Uganda: a pilot randomized clinical trial

  Perioda,b OSNRC SNC
Clinical adverse event 1 0 0
2 0 0
Severe adverse event 1 0 0
2 0 0
pCO2 > 45 mmHg 1 0 0
2 0 0
pH < 7.35 1 2 (25)c 1 (12)
2 1 (17) 2 (25)
Lactate > 3 mmol/L 1 0 2 (25)
2 1 (17)d 0
SpO2 < 90% despite O2 1 0 0
2 0 0
  1. Data represent the number (percent) of patients who experienced an adverse event with OSNRC and SNC (control)
  2. aDuring Period 1, patients were treated with OSNRC (Group A, n = 8) or SNC (Group B, n = 8) for 1 hour
  3. bDuring Period 2, patients were treated with OSNRC (Group B, n = 6) or SNC (Group A, n = 8) for 1 hour
  4. cP > 0.99 for difference between OSNRC and SNC treatments
  5. dP = 0.43 for difference between OSNRC and SNC treatments